6-K ·Filed Jul 23, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001575872-26-000526
Notable filing: 6-K
Actionable Insight • Neutral

The filing contains no actionable information. Monitor for any subsequent disclosure of the exhibit content or other material events. The stock is likely to trade on broader sector trends and prior fundamentals rather than this filing.

DirectionNeutral
Confidencelow
Horizonimmediate
Latest settled — T+20d ⚠ clustered
RDY ▲ +2.63% at T+20d
NEUTRAL call ✓ call won +2.63% · α vs SPY -0.68% · entry $11.80 → $12.11
Next anchor: T+60d in 14d
Latest observation: T+48 +33.26% FF3 residual α
Entry anchored
Jul 23, 11:56 AM ET
via exchange tick
T+1d
-0.08%
call -0.08% · α -0.19%
$11.79
settled 2mo ago
T+5d
+0.25%
call +0.25% · α -0.22%
$11.83
settled 2mo ago
T+20d
+2.63%
call +2.63% · α -0.68%
$12.11
settled 6w ago
T+60d
—
call — · α —
—
in 14d

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's filed a Form 6-K on July 23, 2026, submitting an intimation (Exhibit 99.1) to the SEC. The exhibit content is unavailable in the provided documents, and no material financial or operational disclosures are evident from the filing metadata. This appears to be a routine foreign private issuer report with no immediate stock-moving information.

Key Facts

  • Filed Form 6-K on July 23, 2026, as a report of foreign private issuer.
  • Exhibit 99.1 is referenced but its content is not readable in the provided documents.
  • No financial figures, guidance, or material events are disclosed in the filing text.
  • Prior annual report (20-F) filed May 29, 2026, was routine with no new material disclosures.

Financial Impact

No financial impact identified from the available filing content.

Risk Factors

  • Lack of exhibit content prevents full assessment of the filing's purpose.
  • Routine filings can occasionally precede material announcements, but no such indication is present here.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000526
Document: 0001575872-26-000526-index.html0001575872-26-000526
Document: 0001575872-26-000526.txt0001575872-26-000526
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access